- Home
- BLX vs PVLA Comparison
BLX vs PVLA Comparison
Compare BLX & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLX | PVLA |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | Panama | United States |
| Employees | N/A | 14 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLX | PVLA |
|---|---|---|
| Price | $51.92 | $121.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $171.87 |
| AVG Volume (30 Days) | 119.0K | ★ 246.1K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.22 | N/A |
| Revenue Next Year | $9.84 | $93,193.48 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.14 | $18.23 |
| 52 Week High | $52.31 | $151.18 |
Technical Indicators
Market Signals| Indicator | BLX | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 65.30 | 54.67 |
| Support Level | $43.50 | $85.53 |
| Resistance Level | N/A | $147.47 |
| Average True Range (ATR) | 1.20 | 9.06 |
| MACD | 0.27 | -1.00 |
| Stochastic Oscillator | 99.30 | 57.55 |
Price Performance
Historical ComparisonAbout BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.